v3.26.1
CONVERTIBLE NOTES (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2026
Mar. 25, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Nov. 14, 2025
Short-Term Debt [Line Items]            
Net cash proceeds [1],[2]     $ 1,955 $ 0    
Financial instruments [3] $ 7,276   7,276   $ 0  
Original Secured Note [Member]            
Short-Term Debt [Line Items]            
Principal amount           $ 3,000
Additional Secured Notes [Member]            
Short-Term Debt [Line Items]            
Principal amount $ 1,025   $ 1,025      
Interest rate 24.00%   24.00%      
Maturity date Aug. 12, 2026          
New Note [Member]            
Short-Term Debt [Line Items]            
Interest expense     $ 940      
New Note [Member] | Oramed And Creative Value Capital [Member]            
Short-Term Debt [Line Items]            
Principal amount   $ 10,000        
Interest rate   8.00%        
Additional capacity   $ 10,000        
Net cash proceeds   $ 5,400        
Maturity date   Mar. 25, 2029        
New Note [Member] | Oramed And Creative Value Capital [Member] | Freestanding Warrants [Member]            
Short-Term Debt [Line Items]            
Number of warrants issued   1,851,851        
Exercise price   $ 5.4        
Warrants [Member]            
Short-Term Debt [Line Items]            
Financial instruments $ 2,848   2,848      
Embedded Derivative [Member]            
Short-Term Debt [Line Items]            
Financial instruments 3,197   3,197      
Debt Host [Member]            
Short-Term Debt [Line Items]            
Financial instruments $ 4,079   $ 4,079      
[1] Includes proceeds from issuance of New Notes, derivative liabilities and warrant liabilities to Oramed Pharmaceuticals Inc., a related party, of $4,397 for the three months.
[2] See Note 9 to the condensed consolidated financial statements.
[3] Includes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $6,542 as of March 31, 2026.